A
VERV

AlphaQuest’s Verve Therapeutics VERV Stock Holding History

AlphaQuest’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-39,455
Closed -$443K – 2286
2025
Q2 		$443K Buy
+39,455
New +$225K 0.04% 660
2024
Q2 		– Sell
-18,044
Closed -$240K – 1914
2024
Q1 		$240K Buy
18,044
+15,639
+650% +$207K 0.04% 594
2023
Q4 		$33.5K Buy
+2,405
New +$29.8K 0.01% 927

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

AlphaQuest's VERV Position: Q3 2025 in Review

AlphaQuest sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 39,455 shares — an estimated $443K sold.

AlphaQuest first reported a position in VERV in Q4 2023 and held it in 3 quarters. The position peaked at $443K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • AlphaQuest reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • AlphaQuest sold 39,455 Verve Therapeutics shares in Q3 2025, an estimated $443K.
  • AlphaQuest first reported a position in Verve Therapeutics in Q4 2023 and held it in 3 quarters.
  • AlphaQuest's Verve Therapeutics position peaked at $443K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on AlphaQuest's 13F filing for Q3 2025, filed 3 Nov 2025.